Pacira BioSciences Partners with AmacaThera to Develop Long-Acting Non-Opioid Pain Therapy

Pacira BioSciences, Inc. has announced an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a novel long-acting formulation of ropivacaine designed for postsurgical pain control.

The collaboration aims to expand Pacira’s non-opioid pain management portfolio with a next-generation therapy that offers prolonged pain relief and reduces the need for opioids following surgery.

“Expanding our pipeline with this novel formulation of ropivacaine builds on our leadership in innovative opioid-sparing pain management,” said Frank D. Lee, Chief Executive Officer of Pacira BioSciences. “We believe this franchise-enhancing asset is highly complementary to EXPAREL and underscores our commitment to improving the patient journey with a range of safe and effective pain control options.”

Lee added that the agreement aligns with Pacira’s ‘5×30’ growth strategy, which focuses on advancing clinical-stage, de-risked assets that complement the company’s existing pain management portfolio.

“Given its strong commercial synergies with our current offerings, this asset has the potential to be meaningfully accretive to cash flow and earnings within our 5×30 timeframe,” he said.

AMT-143 represents a promising addition to Pacira’s growing suite of opioid-sparing therapies, aimed at transforming postsurgical recovery and improving outcomes for patients worldwide.